南京威尔药业集团股份有限公司关于股东集中竞价减持股份计划公告

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Nanjing Weier Pharmaceutical Group Co., Ltd., indicating a strategic move to liquidate a portion of their holdings while ensuring that the controlling shareholders will not reduce their stakes [3][10]. Group 1: Major Shareholder Information - Nanjing Shuntai Zonghua Venture Investment Partnership (Limited Partnership) holds 8,788,699 shares, representing approximately 6.49% of the total share capital of the company [2]. - The shares held by Shuntai Zonghua were acquired prior to the initial public offering and through capital reserve conversion [2]. Group 2: Share Reduction Plan Details - The planned reduction will occur from March 23, 2026, to April 10, 2026, with a maximum of 446,340 shares to be sold, equating to no more than 0.33% of the total share capital [3][5]. - The reduction does not include shares held indirectly by the controlling shareholders, ensuring their stakes remain intact during this period [3][6]. Group 3: Management Commitments - Senior management, including Vice President Zou Jianguo, has committed to not exceeding a 25% transfer of their total shareholdings during their tenure, with additional restrictions upon leaving the company [9]. - The management's commitments align with previously disclosed promises regarding shareholding and transfer limits [9].